The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Blood‐based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic
Open accessAbstract
The last decade has seen a substantial increase in research focused on the identification of blood‐based biomarkers that have utility in Alzheimer's disease (AD). Blood‐based biomarkers have significant advantages of being time‐ and cost‐efficient as well as reduced invasiveness and increased patient acceptance. Despite these advantages and increased research efforts, the field has been hampered by lack of reproducibility and an unclear path for moving basic discovery toward clinical utilization. Here we reviewed the recent literature on blood‐based biomarkers in AD to provide a current state of the art. In addition, a collaborative model is proposed that leverages academic and industry strengths to facilitate the field in moving past discovery only work and toward clinical use. Key resources are provided. This new public‐private partnership model is intended to circumvent the traditional handoff model and provide a clear and useful paradigm for the advancement of biomarker science in AD and other neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020124 · Cited by 10,505
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · CHANCE · doi:10.1080/09332480.2005.10722754 · Cited by 4,702
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Self-citationBelieve it or not: how much can we rely on published data on potential drug targets?
Prinz, F., Schlange, T., & Asadullah, K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439-c1 · Cited by 1,888 · cited 1×
“Current model of bio industry personnel) of published studies will not replicate in industrial laboratories [52].”
BackgroundPolicy: NIH plans to enhance reproducibility
Collins, F. S., & Tabak, L. A. (2014) · Nature · doi:10.1038/505612a · Cited by 1,247 · cited 1×
“The National Institutes of Health (NIH) recently outlined a plan to address this problem [50]; however, this is not an issue that can be resolved by academics or industry alone and an updated collaborative model is required.”
Plasma phospholipids identify antecedent memory impairment in older adults
Mapstone, M., Cheema, A. K., Fiandaca, M. S., Zhong, X., Mhyre, T. R., MacArthur, L. H., Hall, W. J., Fisher, S. G., Peterson, D. R., Haley, J. M., et al. (2014) · Nature Medicine · doi:10.1038/nm.3466 · Cited by 1,043
2012 Alzheimer's disease facts and figures Alzheimer's Association ∗
Thies, W., & Bleiler, L. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.02.001 · Cited by 982
Cited by
High performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Self-citationBlood-based biomarkers for Alzheimer's disease: towards clinical implementation
Teunissen, C. E., Verberk, I. M. W., Thijssen, E. H., Vermunt, L., Hansson, O., Zetterberg, H., van der Flier, W. M., Mielke, M. M., & del Campo, M. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00361-6 · Cited by 1,045
Self-citationDiagnosis of Early Alzheimer's Disease: Clinical Practice in 2021
Porsteinsson, A. P., Isaacson, R. S., Knox, S., Sabbagh, M. N., & Rubino, I. (2021) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.23 · Cited by 744
“Significant efforts have been undertaken over the last decade to identify blood-based biomarkers to: 1) detect AD pathology; 2) identify those at risk of developing AD in the future; and 3) monitor disease progression (33, 34, 87).”
Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic
Hampel, H., O’Bryant, S. E., Molinuevo, J. L., Zetterberg, H., Masters, C. L., Lista, S., Kiddle, S. J., Batrla, R., & Blennow, K. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0079-7 · Cited by 716
Self-citationMielke, M. M., Hagen, C. E., Xu, J., Chai, X., Vemuri, P., Lowe, V. J., Airey, D. C., Knopman, D. S., Roberts, R. O., Machulda, M. M., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.013 · Cited by 621
Self-citationCurrent state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518
Self-citationPerformance of plasma phosphorylated tau 181 and 217 in the community
Mielke, M. M., Dage, J. L., Frank, R. D., Algeciras-Schimnich, A., Knopman, D. S., Lowe, V. J., Bu, G., Vemuri, P., Graff-Radford, J., Jack, C. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01822-2 · Cited by 465
Self-citationLiss, J. L., Seleri Assunção, S., Cummings, J., Atri, A., Geldmacher, D. S., Candela, S. F., Devanand, D. P., Fillit, H. M., Susman, J., Mintzer, J., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13244 · Cited by 312
Lewczuk, P., Riederer, P., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramirez, A., Parnetti, L., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 307
Self-citationClinical aspects of Alzheimer's disease
Zvěřová, M. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.04.015 · Cited by 306
Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease
Lewczuk, P., Ermann, N., Andreasson, U., Schultheis, C., Podhorna, J., Spitzer, P., Maler, J. M., Kornhuber, J., Blennow, K., & Zetterberg, H. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0404-9 · Cited by 305
Self-citationDiagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers
Lee, J. C., Kim, S. J., Hong, S., & Kim, Y. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0250-2 · Cited by 253
Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities
Syrjanen, J. A., Campbell, M. R., Algeciras‐Schimnich, A., Vemuri, P., Graff‐Radford, J., Machulda, M. M., Bu, G., Knopman, D. S., Jack, C. R., Petersen, R. C., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12466 · Cited by 253
Self-citationAdvances in the development of new biomarkers for Alzheimer’s disease
Klyucherev, T. O., Olszewski, P., Shalimova, A. A., Chubarev, V. N., Tarasov, V. V., Attwood, M. M., Syvänen, S., & Schiöth, H. B. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00296-z · Cited by 241
“Primary health care facilities could conduct screening to identify patients who may require an additional evaluation by specialists, including CSF diagnostic analysis, MRI, or amyloid PET diagnostics [41].”
BackgroundJanelidze, S., Palmqvist, S., Leuzy, A., Stomrud, E., Verberk, I. M. W., Zetterberg, H., Ashton, N. J., Pesini, P., Sarasa, L., Allué, J. A., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12395 · Cited by 188
Self-citationAmyloid blood biomarker detects Alzheimer's disease
Nabers, A., Perna, L., Lange, J., Mons, U., Schartner, J., Güldenhaupt, J., Saum, K., Janelidze, S., Holleczek, B., Rujescu, D., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708763 · Cited by 185
“…the lack of a clear understanding of their relationship to earliest AD stages and the possibility of being influenced by comorbidities which are common among people with dementia (Fiandaca et al, 2014, 2015; Henriksen et al, 2014; Mapstone et al, 2014; Zhao et al, 2015; O’Bryant et al, 2017).”
BackgroundBrand, A. L., Lawler, P. E., Bollinger, J. G., Li, Y., Schindler, S. E., Li, M., Lopez, S., Ovod, V., Nakamura, A., Shaw, L. M., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01117-1 · Cited by 151
Self-citationAlber, J., Goldfarb, D., Thompson, L. I., Arthur, E., Hernandez, K., Cheng, D., DeBuc, D. C., Cordeiro, F., Provetti‐Cunha, L., den Haan, J., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12006 · Cited by 154
Self-citationAn Update on Blood-Based Markers of Alzheimer’s Disease Using the SiMoA Platform
Li, D., & Mielke, M. M. (2019) · Neurology and Therapy · doi:10.1007/s40120-019-00164-5 · Cited by 147
Self-citationSheinerman, K. S., Toledo, J. B., Tsivinsky, V. G., Irwin, D., Grossman, M., Weintraub, D., Hurtig, H. I., Chen-Plotkin, A., Wolk, D. A., McCluskey, L. F., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0316-0 · Cited by 154
Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention
Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149
Hampel, H., O’Bryant, S. E., Durrleman, S., Younesi, E., Rojkova, K., Escott-Price, V., Corvol, J.-C., Broich, K., Dubois, B., Lista, S., et al. (2017) · Climacteric · doi:10.1080/13697137.2017.1287866 · Cited by 147
Self-citationO'Bryant, S. E., Petersen, M., Hall, J., Johnson, L. A., & for the HABS‐HD Study Team (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12647 · Cited by 110
Self-citationZhao, Y., Xin, Y., Meng, S., He, Z., & Hu, W. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.04.014 · Cited by 105
Gleason, C. E., Zuelsdorff, M., Gooding, D. C., Kind, A. J. H., Johnson, A. L., James, T. T., Lambrou, N. H., Wyman, M. F., Ketchum, F. B., Gee, A., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12511 · Cited by 104
Self-citationPreanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers
Rózga, M., Bittner, T., Batrla, R., & Karl, J. (2019) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.02.002 · Cited by 99
“Methods: Amyloid b peptides (Ab[1-40], Ab[1-42]) and total Tau plasma concentrations were quantified using fully automated Roche Elecsys assays.”
GPS driving: a digital biomarker for preclinical Alzheimer disease
Bayat, S., Babulal, G. M., Schindler, S. E., Fagan, A. M., Morris, J. C., Mihailidis, A., & Roe, C. M. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00852-1 · Cited by 91
“research or assessments involving cerebrospinal fluid (CSF) collection), and availability [9, 10].”
BackgroundMedeiros, G. C., Gould, T. D., Prueitt, W. L., Nanavati, J., Grunebaum, M. F., Farber, N. B., Singh, B., Selvaraj, S., Machado-Vieira, R., Achtyes, E. D., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01652-1 · Cited by 75
“Despite the appeal of brain-based studies, blood-based predictors have the significant advantages of being more easily obtained, more widely accepted by patients, and more likely to be more cost-effective [44, 45].”
BackgroundDayon, L., Cominetti, O., Wojcik, J., Galindo, A. N., Oikonomidi, A., Henry, H., Migliavacca, E., Kussmann, M., Bowman, G. L., & Popp, J. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00809 · Cited by 67
Urinary metabolic phenotyping for Alzheimer’s disease
Kurbatova, N., Garg, M., Whiley, L., Chekmeneva, E., Jiménez, B., Gómez-Romero, M., Pearce, J., Kimhofer, T., D’Hondt, E., Soininen, H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-78031-9 · Cited by 44
Giuliani, D., Ottani, A., Neri, L., Zaffe, D., Grieco, P., Jochem, J., Cavallini, G. M., Catania, A., & Guarini, S. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.11.004 · Cited by 38
Alzheimer’s Disease Clinical Trials: Moving Toward Successful Prevention
Rafii, M. S., & Aisen, P. S. (2019) · CNS Drugs · doi:10.1007/s40263-018-0598-1 · Cited by 36
Vergallo, A., Houot, M., Cavedo, E., Lemercier, P., Vanmechelen, E., De Vos, A., Habert, M., Potier, M., Dubois, B., Lista, S., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.07.001 · Cited by 32
“The development of blood- or plasma-based biomarkers, including BACE1, requires systematic co-development strategies throughout all stages of a clinical trial program, supported by academia, the pharma sector, and regulatory science stakeholder collaboration [4,5].”
BackgroundSelf-citationEpigenetics, early adversity and child and adolescent mental health
Barker, E. D. (2018) · Psychopathology · doi:10.1159/000486683 · Cited by 21
The pathway to secondary prevention of Alzheimer's disease
McDade, E., Bednar, M. M., Brashear, H. R., Miller, D. S., Maruff, P., Randolph, C., Ismail, Z., Carrillo, M. C., Weber, C. J., Bain, L. J., et al. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12069 · Cited by 20
Metadata
- Authors
- O'Bryant, S. E., Mielke, M. M., Rissman, R. A., Lista, S., Vanderstichele, H., Zetterberg, H., Lewczuk, P., Posner, H., Hall, J., Johnson, L., Fong, Y., Luthman, J., Jeromin, A., Batrla‐Utermann, R., Villarreal, A., Britton, G., Snyder, P. J., Henriksen, K., Grammas, P., Gupta, V., Martins, R., Hampel, H., & Area, B. B. B. P. I.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2016-11-18
- Volume
- 13
- Issue
- 1
- Pages
- 45-58
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2550934658
- Cited by
- 303
- References
- 65
- FWCI
- 28.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.